Showing 4711-4720 of 6059 results for "".
- New Survey Reveals Negative Impact of Psoriasis on Mental Healthhttps://practicaldermatology.com/news/new-survey-reveals-negative-impact-of-psoriasis-on-mental-health/2461159/Arcutis Biotherapeutics, Inc. recently shared findings from the Skin Insights: Uncovering Psoriasis Survey, a national survey of 507 adults 18+ diagnosed with plaque psoriasis who are on topical treatments. The online survey was conducted by The Harris Poll and was designed to reveal insight
- ICYMI: Dispatches from The Skin of Color Society’s 18th Annual Scientific Symposiumhttps://practicaldermatology.com/news/icymi-dispatches-from-the-skin-of-color-societys-18th-annual-scientific-symposium/2461157/The Skin of Color Society’s 18th Annual Scientific Symposium wowed the crowd during the American Academ
- Country Music Artist Ashley Barron Named National Scleroderma Foundation’s Celebrity Ambassadorhttps://practicaldermatology.com/news/country-music-artist-ashley-barron-named-national-scleroderma-foundations-celebrity-ambassador/2461155/Country music artist Ashley Barron is the National Scleroderma Foundation’s official Celebrity Ambassador. Barron was diagnosed with scleroderma at age five. At that time, her family had never heard of the disease. Now as Celebrity Ambassador, Barron is working to represent
- Lilly's Lebrikizumab Combined with Topical Corticosteroids Produces Significant Improvements in AD Disease Severityhttps://practicaldermatology.com/news/lillys-lebrikizumab-combined-with-topical-corticosteroids-produces-significant-improvements-in-ad-disease-severity/2461154/Atopic dermatitis patients taking lebrikizumab plus topical steroids showed significant improvements in disease severity, according to study results from the ADhere trial presented at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference. At 16 weeks, 70 percent of
- Scientists Discover Gene Mutation That Signals Aggressive Melanomahttps://practicaldermatology.com/news/scientists-discover-gene-mutation-that-signals-aggressive-melanoma/2461149/Patients whose melanoma tumors have an ARID2 mutation may have a more aggressive cancer and may need to be treated differently, according to a study published in Cell Reports. &l
- Dermatological Society of New Jersey Kicks Off Virtual Conference Saturdayhttps://practicaldermatology.com/news/dermatological-society-of-new-jersey-kicks-off-virtual-conference-saturday/2461147/The DSNJ annual educational conference is a hybrid event this year, with in person as well as online conference experiences open to attendees across the US. The conference is Saturday, April 9. Penn Medicine Princeton Health, accredited by the Medical Society of New Jersey, designa
- Lilly's Olumiant Associated with Significant Hair Growth in Patients with Severe Alopecia Areatahttps://practicaldermatology.com/news/lillys-olumiant-associated-with-significant-hair-growth-in-patients-with-severe-alopecia-areata/2461144/Olumiant® (baricitinib) from Eli Lilly and company produced significant scalp, eyelash, and eyebrow hair regrowth at 52 weeks, with nearly 75% of those who responded to Olumiant 4mg achieving 90% scalp coverage. The 52-week pooled findings were presented at the
- Boehringer Ingelheim’s Effisayil Offers Sustained Relief from GPP Flareshttps://practicaldermatology.com/news/boehringer-ingelheims-effisayil-offers-sustained-releif-from-gpp-flares/2461143/Effisayil (Spesolimab) clears skin pustules in patients with generalized pustular psoriasis (GPP) flares within the first week after treatment, and these benefits are sustained over 12 weeks, according to data presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Bost
- Poster: Interim Data Show Safety, Efficacy of Adbry for More than Three Yearshttps://practicaldermatology.com/news/poster-interim-data-show-safety-efficacy-of-adbry-for-more-than-three-years/2461129/Interim data support the long-term safety and efficacy profile of Adbry™ (tralokinumab-ldrm) for up to 3.5 years in adult patients with moderate-to-severe atopic dermatitis (AD). Results were shared as a
- Compulink Partners with Promptly for New Suite of Serviceshttps://practicaldermatology.com/news/compulink-partners-with-promptly-for-new-suite-of-services/2461127/Compulink Healthcare Solutions has partnered with Promptly to launch Advantage Patient Experience™, a suite of easy-to-use features intended to provide patients with the latest in mobile device convenience, while simultaneously reducing the administrative burden on office staff.